Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSThe Biologics Price Competition and Innovation Act (BPCI Act) of 2009 provided a regulatory pathway for biosimilar products in the United States. Though savings from biosimilars had been slow to build, recently-launched biosimilars have achieved significant uptake within their first year, and the availability and use of biosimilar medicines is on track to reduce drug costs by $100 billion over the next five years. The development and approvals of biosimilars have been accelerating over the past two years, bringing a total of 33 approvals across 13 molecules to date. Details on biosimilar availability and use are presented in this report, along with scenarios for future biosimilar sales and the systemic savings that they may generate in the future.
This report assesses the current state of the biologics market in the United States and finds that the development and approvals of biosimilars have been accelerating. There have been 33 approvals across 13 molecules to date, though biosimilars for two molecules have not yet launched, and 108 additional biosimilars are in development across 22 other molecules. Savings enabled by the presence of biosimilars are modeled to exceed $100 billion in aggregate over the next five years, though volume and price dynamics remain volatile and significant uncertainty remains.
The current biologics market of $211 billion can be segmented into 19% of the market, or $40 billion, already facing some biosimilar competition, 64% or $135 billion potentially open to biosimilar competition, and an additional 17% of the market, or $36 billion, unlikely to ever face biosimilar competitors. Among recent biosimilar launches, bevacizumab, trastuzumab, and rituximab are set to reach nearly 60% share of volume for their respective molecules by the end of their second year on the market — showing significantly higher and faster uptake than prior biosimilars. This reflects efforts by providers to capture available savings, although their adoption has been highly heterogenous, while patients have benefitted from biosimilars in the form of lower out-of-pocket costs. The introduction of biosimilars in some cases has generated 2–4% incremental demand for the molecule. Finally, the report finds that large pharma companies, often with existing innovative biologic portfolios, have dominated the marketing of biosimilars to date, while smaller companies are developing biosimilars but are more likely to license products to a larger company for marketing.
Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years
